









Markets
/
Stocks
/
nasdaq-hrmy
/

Harmony Biosciences Holdings Inc

HRMY

32.980USD

+1.160+3.65%

Close 11/11, 16:00（ET）Quotes delayed by 15 min

1.90BMarket Cap

10.23P/E TTM



Harmony Biosciences Holdings Inc

32.980

+1.160+3.65%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Harmony Biosciences Holdings Inc

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Harmony Biosciences Holdings Inc's Score

Industry at a Glance

Industry Ranking

27 / 159

Overall Ranking

66 / 4608

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

44.545

Target Price

+39.99%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Harmony Biosciences Holdings Inc Highlights

StrengthsRisks

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 63.24% year-on-year.

Undervalued

The company’s latest PE is 10.21, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 48.04M shares, decreasing 24.69% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 42.00K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 9.19, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 239.46M, representing a year-over-year increase of 28.71%, while its net profit experienced a year-over-year increase of 10.35%.

Score

Industry at a Glance

Previous score

9.19

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.22

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.18

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.56

Key Metrics

Free cash flow

No Data

Harmony Biosciences Holdings Inc's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 7.90, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 10.21, which is 96.80% below the recent high of 20.09 and 25.52% above the recent low of 7.60.

Score

Industry at a Glance

Previous score

7.90

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 27/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 7.64, which is lower than the Pharmaceuticals industry's average of 7.77. The average price target for Harmony Biosciences Holdings Inc is 43.00, with a high of 62.00 and a low of 32.00.

Score

Industry at a Glance

Previous score

7.64

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

44.545

Target Price

+39.99%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Harmony Biosciences Holdings Inc

HRMY

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 9.32, which is higher than the Pharmaceuticals industry's average of 7.38. Sideways: Currently, the stock price is trading between the resistance level at 35.68 and the support level at 27.90, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.20

Change

0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

1.105

Buy

RSI(14)

70.078

Buy

STOCH(KDJ)(9,3,3)

92.319

Overbought

ATR(14)

1.434

Low Volatility

CCI(14)

172.487

Buy

Williams %R

5.096

Overbought

TRIX(12,20)

0.451

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

31.704

Buy

MA10

30.536

Buy

MA20

29.095

Buy

MA50

29.825

Buy

MA100

32.453

Buy

MA200

33.056

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 83.41%, representing a quarter-over-quarter decrease of 21.08%. The largest institutional shareholder is The Vanguard, holding a total of 5.09M shares, representing 8.83% of shares outstanding, with 6.88% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Marshman Fund Trust ii

6.05M

BlackRock Institutional Trust Company, N.A.

5.77M

+2.76%

The Vanguard Group, Inc.

Star Investors

5.10M

+8.80%

Fidelity Management & Research Company LLC

4.69M

-12.25%

HBM Partners AG

2.15M

State Street Investment Management (US)

1.63M

+3.18%

LSV Asset Management

1.49M

+24.56%

Dimensional Fund Advisors, L.P.

1.58M

+29.18%

American Century Investment Management, Inc.

1.50M

+16.50%

Marshall Wace LLP

1.21M

+36.27%

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 6.29, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.79. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.